Predicting late magnetic resonance image changes in glioma patients after proton therapy

Authors

  • J. Eulitz OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine, Dresden, Germany;  University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany;  Department of Radiotherapy and Radiation Oncology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;  Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany
  • E.G.C. Troost OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine, Dresden, Germany;  University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany;  Department of Radiotherapy and Radiation Oncology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;  Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany;  National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany;  German Cancer Research Center (DKFZ), Heidelberg, Germany;  Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;  Helmholtz Association/Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany;  German Cancer Consortium (DKTK), Partner Site Dresden, Heidelberg, Germany
  • F. Raschke OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine, Dresden, Germany;  University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany;  Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany
  • E. Schulz OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine, Dresden, Germany; University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany
  • B. Lutz Helmholtz-Zentrum Dresden-Rossendorf, Institute for Radiation Physics, Dresden, Germany
  • A. Dutz OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine, Dresden, Germany;  University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany;  Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany
  • S. Löck OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine, Dresden, Germany;  University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany;  Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany;  German Cancer Research Center (DKFZ), Heidelberg, Germany;  German Cancer Consortium (DKTK), Partner Site Dresden, Heidelberg, Germany
  • P. Wohlfahrt Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
  • W. Enghardt OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine, Dresden, Germany;  University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany;  Department of Radiotherapy and Radiation Oncology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;  Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany;  German Cancer Research Center (DKFZ), Heidelberg, Germany;  German Cancer Consortium (DKTK), Partner Site Dresden, Heidelberg, Germany
  • C. Karpowitz OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine, Dresden, Germany;  University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany;  Department of Radiotherapy and Radiation Oncology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;  Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany;  National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany;  German Cancer Research Center (DKFZ), Heidelberg, Germany;  Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;  Helmholtz Association/Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany;  German Cancer Consortium (DKTK), Partner Site Dresden, Heidelberg, Germany
  • M. Krause OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine, Dresden, Germany;  University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany;  Department of Radiotherapy and Radiation Oncology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;  Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany;  National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany;  German Cancer Research Center (DKFZ), Heidelberg, Germany;  Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;  Helmholtz Association/Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany;  German Cancer Consortium (DKTK), Partner Site Dresden, Heidelberg, Germany
  • A. Lühr OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine, Dresden, Germany;  University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany;  Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany;  German Cancer Research Center (DKFZ), Heidelberg, Germany;  German Cancer Consortium (DKTK), Partner Site Dresden, Heidelberg, Germany

DOI:

https://doi.org/10.1080/0284186X.2019.1631477

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2019-10-03

How to Cite

Eulitz, J., Troost, E., Raschke, F., Schulz, E., Lutz, B., Dutz, A., … Lühr, A. (2019). Predicting late magnetic resonance image changes in glioma patients after proton therapy. Acta Oncologica, 58(10), 1536–1539. https://doi.org/10.1080/0284186X.2019.1631477

Issue

Vol. 58 No. 10 (2019): Acta Oncologica

Section

Articles